FDA approves first drug for spinal muscular atrophy
The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Spinraza is an injection administered into the fluid surrounding the spinal cord.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Children | Food and Drug Administration (FDA) | Genetics | Spinal Muscular Atrophy